Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE versus U GENCIN.
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic